Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 12/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298620 | 0.89 | NISCH (0.58) | NISCH | |
| SCHEMBL9579892 | 0.86 | NISCH (0.81) | NISCH | |
| SCHEMBL3394014 | 0.78 | NISCH (0.65) | NISCH | |
| SCHEMBL16863098 | 0.78 | NISCH (0.76) | NISCH | |
| SCHEMBL1626317 | 0.77 | NISCH (1.00) | NISCH | |
| SCHEMBL2949149 | 0.77 | NISCH (0.62) | NISCH | |
| SCHEMBL80782 | 0.77 | NISCH (0.62) | NISCH | |
| SCHEMBL4818139 | 0.77 | NISCH (0.62) | NISCH | |
| SCHEMBL1882130 | 0.77 | NISCH (0.62) | NISCH | |
| SCHEMBL8887144 | 0.76 | NISCH (0.66) | NISCHCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0817635-B1 | USE OF THIAZEPINE, OXAZEPINE AND DIAZEPINE COUMPOUNDS FOR INHIBITING HIV, HERPESVIRUS AND SUPPRESSING THE IMMUNE SYSTEM | WARNER LAMBERT CO (US) | 2004-06-16 | — | — | EP | claimed |
| CN-103906518-B | Malignant and non-malignant disease treatment using RAS antagonists | 派西斯治疗有限责任公司 | 2020-03-13 | — | — | CN | disclosed |
| US-9738614-B2 | Malignant and non-malignant disease treatment with Ras antagonists | PISCES THERAPEUTICS, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2763681-B1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | PISCES THERAPEUTICS LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20160207891-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | PISCES THERAPEUTICS, LLC (US) | 2016-07-21 | — | — | US | disclosed |
| US-9309203-B2 | Malignant and non-malignant disease treatment with Ras antagonists | PISCES THERAPEUTICS, LLC (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140249163-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | PICES THERAPEUTICS LLC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2763681-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | Pisces Therapeutics LLC (US) | 2014-08-13 | — | — | EP | disclosed |
| CN-103906518-A | Malignant and non-malignant disease treatment using RAS antagonists | PISCES THERAPEUTICS LLC | 2014-07-02 | — | — | CN | disclosed |
| WO-2013052765-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | PISCES THERAPEUTICS LLC (US) | 2013-04-11 | — | — | WO | disclosed |
| US-5612330-A | HERPES VIRUS | WARNER-LAMBERT COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0749434-A1 | BENZOTHIOPHENE, BENZOFURAN AND INDOLETHIAZEPINONES, OXAZEPINONES AND DIAZEPINONES AS INHIBITORS OF CELL ADHESION AND AS INHIBITORS OF HIV | WARNER-LAMBERT COMPANY (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5565446-A | USEFUL IN TREATMENT OF INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996029077-A1 | USE OF THIAZEPINE, OXAZEPINE AND DIAZEPINE COUMPOUNDS FOR INHIBITING HIV, HERPESVIRUS AND SUPPRESSING THE IMMUNE SYSTEM | WARNER-LAMBERT COMPANY (US) | 1996-09-26 | — | — | WO | disclosed |
| US-5489586-A | BENZOTHIOPHEN, BENZOFURAN AND INDOLE-THIAZEPINONES, OXAZEPINONES AND DIAZEPINONES | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995024408-A1 | BENZOTHIOPHENE, BENZOFURAN AND INDOLETHIAZEPINONES, OXAZEPINONES AND DIAZEPINONES AS INHIBITORS OF CELL ADHESION AND AS INHIBITORS OF HIV | WARNER-LAMBERT COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0430334-B1 | Immunostimulating 6-aryl-5,6-dihydroimidazo[2,1-b]thiazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-09-13 | — | — | EP | disclosed |
| US-5140024-A | Thienofuro- or thienodiazepines and pyridofuro- or thienodizsepines; antisecretory and -inflammatory agents; gastrointestinal disorders | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1992-08-18 | — | — | US | disclosed |
| US-4985423-A | New 1,4-diazepine derivatives having anit-ulcer activity | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1991-01-15 | — | — | US | disclosed |
| EP-0350131-A2 | New 1,4-diazepine derivatives having anti-ulcer activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249163-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | HRAS, KRAS, NRAS | NISCH 2496/4885ALDH1A1 3724/4885CYP1A2 4777/4885 |
| US-20160207891-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | HRAS, KRAS, NRAS | NISCH 2496/4885ALDH1A1 3724/4885CYP1A2 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.